XENON
Pulmonary Infection
Mario Castro, MD, MPHSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Pulmonary Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazobactam Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 4 | BB |
Piperacillin Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 4 | BB |
Ciprofloxacin Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Phase 4 | B |
MUREPAVADIN Polyphor Ltd. | Phase 2 | CCC |
Symbicort Maisonneuve-Rosemont Hospital | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
XENON is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →